In the current study, we used US-guided RFA to treat parathyroid hyperplasia in 103 patients with SHPT caused by CKD and showed that serum calcium, phosphorus, and PTH levels decreased significantly after RFA in patients with SHPT, which was consistent with the results of our previous study. The gene discussed is PTH; the disease is parathyroid hyperplasia.